Veeco posts Q2 2026 revenue of $193.5M
Veeco Instruments reported Q2 2026 net sales of $193.5 million, up from $166.1 million a year earlier.
Rhea-AI Filing Summary
Veeco Instruments reported Q2 2026 net sales of $193.5 million, up from $166.1 million a year earlier. GAAP net income was $11.9 million, or $0.18 per diluted share, compared with $11.7 million, or $0.20 per diluted share, in Q2 2025. On a non-GAAP basis, net income was $21.8 million, or $0.33 per diluted share, versus $21.5 million and $0.36 a year ago.
For the six months ended June 30, 2026, net sales were $351.8 million and GAAP net income was $11.5 million. As of June 30, 2026, cash and cash equivalents were $214.5 million, short-term investments were $214.9 million, long-term debt was $226.5 million, and stockholders’ equity totaled $902.8 million.
For Q3 2026, Veeco guides net sales to $200–$220 million, GAAP diluted EPS to $0.20–$0.35, and non-GAAP diluted EPS to $0.34–$0.49. Full-year 2026 guidance calls for net sales of $780–$810 million, GAAP diluted EPS of $0.78–$1.36, and non-GAAP diluted EPS of $1.02–$1.61. Management highlights AI-driven demand for its semiconductor process equipment and notes that its outlook is subject to risks, including completion of a pending merger with Axcelis and global trade conditions.
Positive
- Q2 2026 net sales reached $193.5M, up from $166.1M in Q2 2025, delivering double-digit year-over-year revenue growth.
Negative
- GAAP diluted EPS declined to $0.18 in Q2 2026 from $0.20 a year earlier, as higher operating expenses, including merger-related costs, offset revenue growth.
Filing Explained
The headline’s strength is sales-led, while GAAP diluted EPS declined year over year.
The August 5 Form 8-K reports the completed quarter ended
Form 8-K reports specified material events, and this filing uses Item 2.02 for results of operations and financial condition. The filing states that the Item 2.02 and 9.01 information is furnished, so it is not deemed filed for Section 18 purposes or incorporated by reference except through specific reference.
Non-GAAP results exclude items including share-based compensation, amortization, restructuring-related charges, and acquisition-related items, so the non-GAAP figures are supplemental rather than substitutes for GAAP results. Q2 diluted EPS used 66,782 thousand weighted-average shares, including 1,972 thousand potentially dilutive awards and 3,746 thousand from the 2029 convertible senior notes, compared with 61,064 thousand basic shares.
8-K Event Classification
Key Figures
Key Terms
Non-GAAP financial measures financial
Convertible Senior Notes financial
operating lease right-of-use assets financial
contract assets financial
Earnings Snapshot
For Q3 2026, Veeco guides net sales to $200–$220 million with GAAP diluted EPS of $0.20–$0.35 and non-GAAP diluted EPS of $0.34–$0.49. For full-year 2026, it expects net sales of $780–$810 million, GAAP diluted EPS of $0.78–$1.36, and non-GAAP diluted EPS of $1.02–$1.61.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Veeco Instruments (VECO) Q2 2026 revenue and earnings?
How did Veeco Instruments (VECO) GAAP and non-GAAP results compare in Q2 2026?
What guidance did Veeco Instruments (VECO) provide for Q3 2026?
What is Veeco Instruments (VECO) full-year 2026 financial outlook?
What does the Veeco Instruments (VECO) balance sheet show after Q2 2026?
How does the pending Axcelis merger factor into Veeco Instruments (VECO) outlook?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
(Address of principal executive offices)
(
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 5, 2026, Veeco Instruments Inc. (“Veeco”) issued a press release announcing its financial results for the quarter ended June 30, 2026. In connection with the release and the related conference call, Veeco posted a presentation relating to its second quarter 2026 financial results on its website (www.veeco.com). Copies of the press release and presentation are furnished as Exhibit 99.1 and Exhibit 99.2 to this report.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
EXHIBIT INDEX
Exhibit | | Description |
99.1 | Press release issued by Veeco dated August 5, 2026 | |
99.2 | Veeco Q2 2026 Conference Call Presentation August 5, 2026 | |
104 | Cover Page Interactive Data File (formatted as inline XBRL). |
Limitation on Incorporation by Reference
In accordance with general instruction B.2 of Form 8-K, the information in this report, including exhibits, is furnished pursuant to Items 2.02 and 9.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall this information or exhibits be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
August 5, 2026 | VEECO INSTRUMENTS INC. | |
By: | /s/ Kirk Mackey | |
Name: Kirk Mackey | ||
Title: Vice President, General Counsel | ||
EXHIBIT 99.1
VEECO REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
Second Quarter 2026 Highlights:
| ● | Revenue of $193.5 million, compared with $166.1 million in the same period last year |
| ● | GAAP net income of $11.9 million, or $0.18 per diluted share, compared with $11.7 million, or $0.20 earnings per diluted share in the same period last year |
| ● | Non-GAAP net income of $21.8 million, or $0.33 per diluted share, compared with $21.5 million, or $0.36 per diluted share in the same period last year |
Plainview, N.Y., August 5, 2026 -- Veeco Instruments Inc. (Nasdaq: VECO) today announced financial results for its second quarter ended June 30, 2026. Results are reported in accordance with U.S. generally accepted accounting principles (“GAAP”) and are also reported adjusting for certain items (“Non-GAAP”). A reconciliation between GAAP and Non-GAAP operating results is provided at the end of this press release.
U.S. Dollars in millions, except per share data |
GAAP Results |
| Q2 '26 | | Q2 '25 | ||
Revenue | | $ | 193.5 | | $ | 166.1 |
Net income | | $ | 11.9 | | $ | 11.7 |
Diluted earnings per share | | $ | 0.18 | | $ | 0.20 |
Non-GAAP Results |
| Q2 '26 | | Q2 '25 | ||
Operating income | | $ | 23.1 | | $ | 23.1 |
Net income | | $ | 21.8 | | $ | 21.5 |
Diluted earnings per share | | $ | 0.33 | | $ | 0.36 |
“Veeco delivered strong quarterly results, exceeding market expectations while continuing to build momentum across our business,” said Bill Miller, Ph.D., Veeco’s Chief Executive Officer. “The rapid expansion of AI is driving increased demand across our broad portfolio of advanced technologies, resulting in robust order activity and deeper customer engagement throughout our markets. Supported by growing visibility into 2027 and the execution of our manufacturing expansion strategy, we remain confident in our long-term growth outlook.”
1
Guidance and Outlook
The following guidance is provided for Veeco’s third quarter 2026:
| ● | Revenue is expected in the range of $200 million to $220 million |
| ● | GAAP diluted earnings per share are expected in the range of $0.20 to $0.34 |
| ● | Non-GAAP diluted earnings per share are expected in the range of $0.35 to $0.49 |
The following revised guidance is provided for Veeco’s fiscal year 2026:
| ● | Revenue is expected in the range of $780 million to $810 million |
| ● | GAAP diluted earnings per share are expected in the range of $0.78 to $1.02 |
| ● | Non-GAAP diluted earnings per share are expected in the range of $1.36 to $1.61 |
Conference Call Information
A conference call reviewing these results has been scheduled for today, August 5, 2026 starting at 5:00pm ET. To join the call, dial 1-877-407-8029 (toll-free) or 1-201-689-8029. Participants may also access a live webcast of the call by visiting the investor relations section of Veeco's website at ir.veeco.com. A replay of the webcast will be made available on the Veeco website that evening. We will post an accompanying slide presentation to our website prior to the beginning of the call.
About Veeco
Veeco (NASDAQ: VECO) is an innovative manufacturer of semiconductor process equipment. Our laser annealing, ion beam, metal organic chemical vapor deposition (MOCVD), single wafer etch & clean and lithography technologies play an integral role in the fabrication and packaging of advanced semiconductor devices. With equipment designed to optimize performance, yield and cost of ownership, Veeco holds leading technology positions in the markets we serve. To learn more about Veeco’s systems and service offerings, visit www.veeco.com.
No Offer or Solicitation
This communication is not intended to and shall not constitute an offer to purchase or the solicitation of an offer to buy or sell any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Forward-looking Statements
This press release contains “forward-looking statements”, within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, as amended, that are based on management’s expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements. Forward-looking statements include, but are not limited to, those regarding anticipated growth and trends in our businesses and markets, including trends related to artificial intelligence and high-performance computing, industry outlooks and demand drivers, statements regarding the pending merger with Axcelis, the timing of shipments, deliveries and revenue recognition, statements regarding shipments currently being held by U.S. Customs, our investment and growth strategies, our development of new products and technologies, our business outlook for current and future periods, our ongoing transformation initiative and the effects thereof on our operations and financial results, the timing, completion and expected benefits of the proposed transaction and other statements that are not historical facts. These statements and their underlying assumptions are subject to risks and uncertainties and are not guarantees of future performance. Factors that could cause actual results to differ materially from those expressed or implied by such statements include, without limitation: the level of demand for our products; global economic and industry conditions; global trade issues, including the effects of foreign and domestic tariffs and the ongoing trade disputes between the U.S. and China, and changes in trade and export license policies; our dependency on third-party suppliers and outsourcing partners; the timing of customer orders; our ability to develop, deliver and support new products and technologies; our ability to expand our current markets, increase market share and develop new markets; the concentrated nature of our customer base; cybersecurity attacks and our ability to safeguard sensitive information and protect our intellectual property rights in key technologies; the effects of regional or global health epidemics; delays in or failure to complete the proposed transaction, whether due to an inability by either party to satisfy one or more conditions to closing, including an inability to obtain regulatory approval in China, the occurrence of events or changes in circumstances that give rise to the termination of the applicable merger agreement by either party, or otherwise; risks related to the pendency of the proposed transaction and its effect on our business, financial condition, results of operations, cash flows and stock price; our ability to achieve the objectives of operational and strategic initiatives and attract, motivate and retain key employees, including as a result of the proposed transaction; diversion of management time and attention from ordinary course business operations to the proposed transaction and other potential disruptions to our business relating thereto; the variability of
2
results among products and end-markets, and our ability to accurately forecast future results, market conditions, and customer requirements; the impact of our indebtedness, including our convertible senior notes and our capped call transactions; and other risks and uncertainties described in our SEC filings on Forms 10-K, 10-Q and 8-K, and from time-to-time in our other SEC reports. All forward-looking statements speak only to management’s expectations, estimates, projections and assumptions as of the date of this press release. The Company does not undertake any obligation to update or publicly revise any forward-looking statements to reflect events, circumstances or changes in expectations after the date of this press release.
-financial tables attached-
Veeco Contacts:
Investor Relations: Alex Delacroix (516) 528-1020adelacroix@veeco.com
Media: Brenden Wright (410) 984-2610bwright@veeco.com
3
Veeco Instruments Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
(unaudited)
| | Three months ended June 30, | | Six months ended June 30, |
| ||||||||
| | 2026 | | 2025 | | 2026 | | 2025 |
| ||||
Net sales |
| $ | 193,481 |
| $ | 166,104 |
| $ | 351,822 |
| $ | 333,396 | |
Cost of sales | |
| 118,649 | |
| 97,377 | |
| 221,162 | |
| 196,202 | |
Gross profit | |
| 74,832 | |
| 68,727 | |
| 130,660 | |
| 137,194 | |
Operating expenses, net: | | | | | | | | | | | | | |
Research and development | |
| 33,343 | |
| 31,560 | |
| 63,218 | |
| 60,074 | |
Selling, general, and administrative | |
| 27,629 | |
| 23,927 | |
| 53,645 | |
| 48,955 | |
Amortization of intangible assets | |
| 607 | |
| 821 | |
| 1,312 | |
| 1,642 | |
Merger costs | |
| 1,464 | |
| — | |
| 3,476 | |
| — | |
Other operating expense (income), net | |
| (64) | |
| 49 | |
| (186) | |
| 5 | |
Total operating expenses, net | |
| 62,979 | |
| 56,357 | |
| 121,465 | |
| 110,676 | |
Operating income | |
| 11,853 | |
| 12,370 | |
| 9,195 | |
| 26,518 | |
Interest income (expense), net | |
| 1,171 | |
| 905 | |
| 2,346 | |
| 1,741 | |
Other income (expense), net | | | — | | | (653) | | | — | | | (653) | |
Income before income taxes | |
| 13,024 | |
| 12,622 | |
| 11,541 | |
| 27,606 | |
Income tax expense | |
| 1,167 | |
| 889 | |
| 8 | |
| 3,926 | |
Net income |
| $ | 11,857 |
| $ | 11,733 |
| $ | 11,533 |
| $ | 23,680 | |
| | | | | | | | | | | | | |
Income per common share: | | | | | | | | | | | | | |
Basic |
| $ | 0.19 |
| $ | 0.20 |
| $ | 0.19 |
| $ | 0.41 | |
Diluted |
| $ | 0.18 |
| $ | 0.20 |
| $ | 0.18 |
| $ | 0.40 | |
| | | | | | | | | | | | | |
Weighted average number of shares: | | | | | | | | | | | | | |
Basic | |
| 61,064 | |
| 59,076 | |
| 60,777 | |
| 58,434 | |
Diluted | |
| 66,782 | |
| 60,237 | |
| 64,936 | |
| 60,072 | |
4
Veeco Instruments Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands)
| | June 30, | | December 31, | ||
| | 2026 | | 2025 | ||
| | (unaudited) | | | | |
Assets | | | | | | |
Current assets: | | | | | | |
Cash and cash equivalents | | $ | 214,458 | | $ | 163,466 |
Short-term investments | |
| 214,940 | |
| 226,763 |
Accounts receivable, net | |
| 148,369 | |
| 110,685 |
Contract assets | |
| 23,430 | |
| 34,838 |
Inventories | |
| 292,495 | |
| 275,298 |
Prepaid expenses and other current assets | |
| 36,582 | |
| 34,286 |
Total current assets | |
| 930,274 | |
| 845,336 |
Property, plant and equipment, net | |
| 110,265 | |
| 108,646 |
Operating lease right-of-use assets | | | 23,634 | |
| 24,606 |
Intangible assets, net | |
| 4,384 | |
| 5,696 |
Goodwill | |
| 214,964 | |
| 214,964 |
Deferred income taxes | |
| 124,045 | |
| 122,935 |
Other assets | |
| 6,899 | |
| 3,612 |
Total assets | | $ | 1,414,465 | | $ | 1,325,795 |
| | | | | | |
Liabilities and stockholders’ equity | | | | | | |
Current liabilities: | | | | | | |
Accounts payable | | $ | 57,480 | | $ | 55,345 |
Accrued expenses and other current liabilities | |
| 54,087 | |
| 45,503 |
Contract liabilities | |
| 123,682 | |
| 74,161 |
Income taxes payable | |
| 1,720 | |
| 3,048 |
Total current liabilities | |
| 236,969 | |
| 178,057 |
Deferred income taxes | |
| 492 | |
| 532 |
Long-term debt | |
| 226,543 | |
| 226,009 |
Long-term operating lease liabilities | | | 30,470 | |
| 31,837 |
Other liabilities | |
| 17,209 | |
| 3,852 |
Total liabilities | |
| 511,683 | |
| 440,287 |
| | | | | | |
Total stockholders’ equity | |
| 902,782 | |
| 885,508 |
Total liabilities and stockholders’ equity | | $ | 1,414,465 | | $ | 1,325,795 |
Note on Reconciliation Tables
The below tables include financial measures adjusted for the impact of certain items; these financial measures are therefore not calculated in accordance with GAAP. These Non-GAAP financial measures exclude items such as: share-based compensation expense; charges relating to restructuring initiatives; non-cash asset impairments; certain other non-operating gains and losses; and acquisition-related items such as transaction costs, non-cash amortization of acquired intangible assets, and certain integration costs.
These Non-GAAP financial measures may be different from Non-GAAP financial measures used by other companies. Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. By excluding these items, Non-GAAP financial measures are intended to facilitate meaningful comparisons to historical operating results, competitors’ operating results, and estimates made by securities analysts. Management is evaluated on key performance metrics including Non-GAAP Operating income (loss), which is used to determine management incentive compensation as well as to forecast future periods. These Non-GAAP financial measures may be useful to investors in allowing for greater transparency of supplemental information used by management in its financial and operational decision-making. In addition, similar Non-GAAP financial measures have historically been reported to investors; the inclusion of comparable numbers provides consistency in financial reporting. Investors are encouraged to review the reconciliation of the Non-GAAP financial measures used in this news release to their most directly comparable GAAP financial measures.
5
Reconciliation of GAAP to Non-GAAP Financial Data (Q2 2026)
(in thousands)
(unaudited)
| | | | | Non-GAAP Adjustments | | | |
| ||||
| | | | | Share-Based | | | | | | | |
|
Three months ended June 30, 2026 | | GAAP | | Compensation | | Amortization | | Other | | Non-GAAP |
| ||
Net sales | | $ | 193,481 | | | | | | | | $ | 193,481 |
|
Gross profit |
| | 74,832 |
| 1,600 | | |
| |
| | 76,432 | |
Gross margin |
| | 38.7 | % | | | | | |
| | 39.5 | % |
Operating expenses |
| | 62,979 |
| (7,615) | | (607) | | (1,464) | | | 53,293 | |
Operating income |
| | 11,853 |
| 9,215 | | 607 |
| 1,464 | ^ | | 23,139 | |
Net income |
| | 11,857 |
| 9,215 |
| 607 |
| 71 | ^ | | 21,750 | |
^ | - See table below for additional details. |
Other Non-GAAP Adjustments (Q2 2026)
(in thousands)
(unaudited)
Three months ended June 30, 2026 | | |
Merger related expenses | $ | 1,464 |
Subtotal | | 1,464 |
Non-cash interest expense |
| 290 |
Non-GAAP tax adjustment * |
| (1,683) |
Total Other | $ | 71 |
* | - The ‘with or without’ method is utilized to determine the income tax effect of all Non-GAAP adjustments. |
Net Income per Common Share (Q2 2026)
(in thousands, except per share amounts)
(unaudited)
| | Three months ended June 30, 2026 | ||||
| | GAAP | | Non-GAAP | ||
Numerator: | | | | | | |
Net income available to common shareholders | | $ | 11,857 | | $ | 21,750 |
| | | | | | |
Denominator: | | | | | | |
Basic weighted average shares outstanding | | | 61,064 | | | 61,064 |
Effect of potentially dilutive share-based awards | | | 1,972 | | | 1,972 |
Dilutive effect of 2029 Convertible Senior Notes | |
| 3,746 |
|
| 3,746 |
Diluted weighted average shares outstanding | | | 66,782 | | | 66,782 |
| | | | | | |
Net income per common share: | | | | | | |
Basic | | $ | 0.19 | | $ | 0.36 |
Diluted | | $ | 0.18 | | $ | 0.33 |
6
Reconciliation of GAAP to Non-GAAP Financial Data (Q2 2025)
(in thousands)
(unaudited)
| | | | | Non-GAAP Adjustments | |
| | | ||||
| | | | | Share-based | | | | | | | | |
Three months ended June 30, 2025 | | | GAAP | | Compensation | | Amortization | | Other | | Non-GAAP | | |
Net sales | | $ | 166,104 | | | | | | | | $ | 166,104 | |
Gross profit | |
| 68,727 |
| 1,991 | | |
| | |
| 70,718 | |
Gross margin | |
| 41.4 | % | | | | | | | | 42.6 | % |
Operating expenses | |
| 56,357 |
| (7,660) | | (821) | | (255) | | | 47,621 | |
Operating income | |
| 12,370 |
| 9,651 | | 821 |
| 255 | ^ | | 23,097 | |
Net income | |
| 11,733 |
| 9,651 |
| 821 |
| (670) | ^ | | 21,535 | |
^ | - See table below for additional details. |
Other Non-GAAP Adjustments (Q2 2025)
(in thousands)
(unaudited)
Three months ended June 30, 2025 | | |
Other | $ | 255 |
Subtotal | | 255 |
Non-cash interest expense |
| 292 |
Other (income) expense, net | | 653 |
Non-GAAP tax adjustment * |
| (1,870) |
Total Other | $ | (670) |
* | - The ‘with or without’ method is utilized to determine the income tax effect of all Non-GAAP adjustments. |
Net Income per Common Share (Q2 2025)
(in thousands, except per share amounts)
(unaudited)
| | Three months ended June 30, 2025 | ||||
| | GAAP | | Non-GAAP | ||
Numerator: | | | | | | |
Net income | | $ | 11,733 | | $ | 21,535 |
Interest expense associated with 2025 and 2027 Convertible Senior Notes | |
| 125 |
|
| 113 |
Net income available to common shareholders | | $ | 11,858 | | $ | 21,648 |
| | | | | | |
Denominator: | | | | | | |
Basic weighted average shares outstanding | | | 59,076 | | | 59,076 |
Effect of potentially dilutive share-based awards | | | 257 | | | 257 |
Dilutive effect of 2027 Convertible Senior Notes (1) | |
| 904 |
|
| 685 |
Diluted weighted average shares outstanding | | | 60,237 | | | 60,018 |
| | | | | | |
Net income per common share: | | | | | | |
Basic | | $ | 0.20 | | $ | 0.36 |
Diluted | | $ | 0.20 | | $ | 0.36 |
| (1) | - The non-GAAP incremental dilutive shares includes the impact of the Company’s capped call transaction issued concurrently with our 2027 Notes, and as such, an effective conversion price of $18.46 is used when determining incremental shares to add to the dilutive share count. The GAAP incremental dilutive shares does not include the impact of the Company’s capped call transaction, and as such, an effective conversion price of $13.98 is used when determining incremental shares to add to the dilutive share count. |
7
Reconciliation of GAAP Net Income to Non-GAAP Operating Income (Q2 2026 and 2025)
(in thousands)
(unaudited)
| | Three months ended | | Three months ended | ||
| | June 30, 2026 | | June 30, 2025 | ||
GAAP Net income | | $ | 11,857 | | $ | 11,733 |
Share-based compensation | |
| 9,215 | |
| 9,651 |
Amortization | |
| 607 | |
| 821 |
Merger related expenses | |
| 1,464 | |
| — |
Interest (income) expense, net | |
| (1,171) | |
| (905) |
Other | | | — | | | 908 |
Income tax expense (benefit) | |
| 1,167 | |
| 889 |
Non-GAAP Operating income | | $ | 23,139 | | $ | 23,097 |
Reconciliation of GAAP to Non-GAAP Financial Data (Q3 2026)
(in millions, except per share amounts)
(unaudited)
| | | | | | | | | | Non-GAAP Adjustments | | | | | | | | |
| ||||
Guidance for the three months ending | | | | | | | | | | Share-based | | | | | | | | | | | | |
|
September 30, 2026 | | GAAP | | Compensation | | Amortization | | Other | | Non-GAAP |
| ||||||||||||
Net sales | | $ | 200 | | - | | $ | 220 | | | | | | | | $ | 200 | | - | | $ | 220 | |
Gross profit | |
| 80 |
| - | |
| 92 |
| 1 |
| — |
| — | |
| 82 |
| - | |
| 93 | |
Gross margin | |
| 40% | | - | |
| 42% | | |
| |
| | |
| 41% | | - | |
| 42% | |
Operating expenses | | | 66 |
| - | |
| 67 | | (8) | | — | | (1) | | | 57 |
| - | |
| 58 | |
Operating income | | | 14 | | - | | | 25 | | 9 | | — | | 1 | | | 25 | | - | | | 35 | |
Net income | | $ | 14 |
| - | | $ | 23 |
| 9 |
| — | | — | | $ | 23 |
| - | | $ | 33 | |
| | | | | | | | | | | | | | | | | | | | | | | |
Income per diluted common share | | $ | 0.20 |
| - | | $ | 0.34 |
| |
| |
| | | $ | 0.35 |
| - | | $ | 0.49 | |
Income per Diluted Common Share (Q3 2026)
(in millions, except per share amounts)
(unaudited)
Guidance for the three months ending September 30, 2026 | | GAAP | | Non-GAAP | ||||||||||||
Numerator: | | | | | | | | | | | | | | | | |
Net income available to common shareholders | | $ | 14 | | - | | $ | 23 | | $ | 23 | | - | | $ | 33 |
| | | | | | | | | | | | | | | | |
Denominator: | | | | | | | | | | | | | | | | |
Basic weighted average shares outstanding | | | 61 | | - | | | 61 | | | 61 | | - | | | 61 |
Effect of potentially dilutive share-based awards | | | 2 |
| - | | | 2 | | | 2 |
| - | | | 2 |
Dilutive effect of 2029 Convertible Senior Notes | |
| 4 | | - | |
| 4 |
|
| 4 | | - | |
| 4 |
Diluted weighted average shares outstanding | | | 67 | | - | | | 67 | | | 67 | | - | | | 67 |
| | | | | | | | | | | | | | | | |
Net income per common share: | | | | | | | | | | | | | | | | |
Income per diluted common share | | $ | 0.20 | | - | | $ | 0.34 | | $ | 0.35 | | - | | $ | 0.49 |
8
Reconciliation of GAAP Net Income to Non-GAAP Operating Income (Q3 2026)
(in millions)
(unaudited)
Guidance for the three months ending September 30, 2026 | | | | | | | | |
GAAP Net income | | $ | 14 |
| - | | $ | 23 |
Share-based compensation | |
| 9 |
| - | |
| 9 |
Merger related expense | | | 1 | | - | | | 1 |
Interest expense (income) | | | (1) | | - | | | (1) |
Income tax expense | | | 2 | | - | | | 3 |
Non-GAAP Operating income | | $ | 25 |
| - | | $ | 35 |
Note: Amounts may not calculate precisely due to rounding.
Reconciliation of GAAP to Non-GAAP Financial Data (FY 2026)
(in millions, except per share amounts)
(unaudited)
| | | | | | | | | | Non-GAAP Adjustments | | | | | | | | | ||||
Guidance for the year ending | | | | | | | | | | Share-based | | | | | | | | | | | | |
December 31, 2026 | | GAAP | | Compensation | | Amortization | | Other | | Non-GAAP | ||||||||||||
Net sales | | $ | 780 | | - | | $ | 810 | | | | | | | | $ | 780 | | - | | $ | 810 |
Gross profit | |
| 306 |
| - | |
| 334 |
| 6 |
| — |
| — | |
| 312 |
| - | |
| 340 |
Gross margin | |
| 39% | | - | |
| 41% | | |
| |
| | |
| 40% | | - | |
| 42% |
Operating expenses | | | 253 |
| - | |
| 263 | | (30) | | (2) | | (6) | | | 215 |
| - | |
| 225 |
Operating income | | | 53 | | - | | | 71 | | 36 | | 2 | | 6 | | | 97 | | - | | | 115 |
Net income | | $ | 52 |
| - | | $ | 68 |
| 36 |
| 2 | | 1 | | $ | 91 |
| - | | $ | 107 |
| | | | | | | | | | | | | | | | | | | | | | |
Income per diluted common share | | $ | 0.78 |
| - | | $ | 1.02 |
| |
| |
| | | $ | 1.36 |
| - | | $ | 1.61 |
Income per Diluted Common Share (FY 2026)
(in millions, except per share amounts)
(unaudited)
Guidance for the year ending December 31, 2026 | | GAAP | | Non-GAAP | ||||||||||||
Numerator: | | | | | | | | | | | | | | | | |
Net income available to common shareholders | | $ | 52 | | - | | $ | 68 | | $ | 91 | | - | | $ | 107 |
| | | | | | | | | | | | | | | | |
Denominator: | | | | | | | | | | | | | | | | |
Basic weighted average shares outstanding | | | 62 | | - | | | 62 | | | 62 | | - | | | 62 |
Effect of potentially dilutive share-based awards | | | 1 |
| - | | | 1 | | | 1 |
| - | | | 1 |
Dilutive effect of 2029 Convertible Senior Notes | |
| 4 | | - | |
| 4 |
|
| 4 | | - | |
| 4 |
Diluted weighted average shares outstanding | | | 67 | | - | | | 67 | | | 67 | | - | | | 67 |
| | | | | | | | | | | | | | | | |
Net income per common share: | | | | | | | | | | | | | | | | |
Income per diluted common share | | $ | 0.78 | | - | | $ | 1.02 | | $ | 1.36 | | - | | $ | 1.61 |
9
Reconciliation of GAAP Net Income to Non-GAAP Operating Income (FY 2026)
(in millions)
(unaudited)
Guidance for the year ending December 31, 2026 | | | | | | | | |
GAAP Net income | | $ | 52 |
| - | | $ | 68 |
Share-based compensation | |
| 36 |
| - | |
| 36 |
Amortization | |
| 2 |
| - | |
| 2 |
Merger related expense | | | 6 | | - | | | 6 |
Interest expense (income) | | | (4) | | - | | | (4) |
Income tax expense | | | 5 | | - | | | 7 |
Non-GAAP Operating income | | $ | 97 |
| - | | $ | 115 |
10
Exhibit 99.2
| Q2 2026 Financial Results Conference Call August 5th, 2026 Veeco Instruments 1 |
| 2 Disclaimer No Offer or Solicitation This communication is not intended to and shall not constitute an offer to purchase or the solicitation of an offer to buy or sell any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. Forward-looking Statements This presentation contains “forward-looking statements”, within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, as amended, that are based on management’s expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements. Forward-looking statements include, but are not limited to, those regarding anticipated growth and trends in our businesses and markets, industry outlooks and demand drivers, including trends related to artificial intelligence and high-performance computing, statements regarding the pending merger with Axcelis, the timing of shipments, deliveries and revenue recognition, statements regarding shipments currently being held by U.S. Customers, our investment and growth strategies, our development of new products and technologies, our business outlook for current and future periods, our ongoing transformation initiative and the effects thereof on our operations and financial results, the timing, completion and expected benefits of the proposed transaction and other statements that are not historical facts. These statements and their underlying assumptions are subject to risks and uncertainties and are not guarantees of future performance. Factors that could cause actual results to differ materially from those expressed or implied by such statements include, without limitation: the level of demand for our products; global economic and industry conditions; global trade issues, including the effects of foreign and domestic tariffs and the ongoing trade disputes between the U.S. and China, and changes in trade and export license policies; our dependency on third-party suppliers and outsourcing partners; the timing of customer orders; our ability to develop, deliver and support new products and technologies; our ability to expand our current markets, increase market share and develop new markets; the concentrated nature of our customer base; cybersecurity attacks and our ability to safeguard sensitive information and protect our intellectual property rights in key technologies; the effects of regional or global health epidemics; delays in or failure to complete the proposed transaction, whether due to an inability by either party to satisfy one or more conditions to closing, including an inability to obtain regulatory approval in China, the occurrence of events or changes in circumstances that give rise to the termination of the applicable merger agreement by either party, or otherwise; risks related to the pendency of the proposed transaction and its effect on our business, financial condition, results of operations, cash flows and stock price; our ability to achieve the objectives of operational and strategic initiatives and attract, motivate and retain key employees, including as a result of the proposed transaction; diversion of management time and attention from ordinary course business operations to the proposed transaction and other potential disruptions to our business relating thereto; the variability of results among products and end-markets, and our ability to accurately forecast future results, market conditions, and customer requirements; the impact of our indebtedness, including our convertible senior notes and our capped call transactions; and other risks and uncertainties described in our SEC filings on Forms 10-K, 10-Q and 8-K, and from time-to-time in our other SEC reports. All forward-looking statements speak only to management’s expectations, estimates, projections and assumptions as of the date of this presentation. The Company does not undertake any obligation to update or publicly revise any forward-looking statements to reflect events, circumstances or changes in expectations after the date of this presentation. Non-GAAP Financial Measures This presentation also includes references to financial measures that are calculated and presented on the basis of methodologies other than in accordance with generally accepted accounting principles in the United States of America (“GAAP”). These non-GAAP measures include, but are not limited to, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP operating income, non-GAAP net income and non-GAAP diluted earnings per share. Any non-GAAP financial measures used in this presentation are in addition to, and should not be considered superior to, or a substitute for, financial statements prepared in accordance with GAAP. Non-GAAP financial measures should not be considered in isolation or as an alternative to financial statements prepared in accordance with GAAP and are subject to significant inherent limitations. We believe these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to Veeco's financial condition and results of operations. The non-GAAP measures presented herein should not be comparable to similar non-GAAP measures presented by other companies. These non-GAAP financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures. A reconciliation of non-GAAP financial measures used in this presentation to the most directly comparable GAAP financial measures is included in the Appendix. |
| Bill Miller, Ph.D. CEO Overview 3 |
| 4 Q2 2026 Highlights 1. Strong performance and street beat 2. Acceleration of order momentum across all major end markets; strengthening 2027 visibility • Secured $200M in Advanced Packaging orders 3. Executing manufacturing expansion plan; deliberate investments ahead of 2027 revenue 4. Achieved major milestones for next-generation NSA program Revenue $193M Non-GAAP Operating Income $23M Non-GAAP EPS 0.33₵ Key Takeaways |
| 2026 2030 Total Served Available Market Annealing IBD Advanced Packaging Services & Other 5 Veeco’s Critical Role in Semi Manufacturing & SAM Expansion Deposition Lithography Etch Ion Implant Anneal Inspection Adv. Packaging IBD 300 IBD EUV LSA Wet Processing Litho FRONT END Representative Process Steps BACK END NSA Key Process 2026 2030 Annealing Laser Spike Annealing (LSA) ~$800M ~$1.3B Nanosecond Annealing (NSA) Ion Beam Deposition IBD300 Front End Semi ~$120M ~$500M IBD Extreme Ultraviolet (EUV) Mask Blanks & Pellicles Advanced Packaging Wet Processing and Lithography ~$600M ~$1.0B Projected ~12% CAGR ~$1.7B ~$3.0B New products Driving revenue |
| 6 Compound Semi Projected SAM Growth Source: Veeco Served Available Market based on TrendFocus, Gartner, Yole Group and internal analysis Key Driver 2026 2030 Silicon Photonics (InP Lasers) • Lumina® MOCVD InP platform • WaferEtch® and WaferStorm® systems • Spector® IBD for laser diode facets coatings ~$300M ~$700M Other Photonics • Lumina® MOCVD platform for red MicroLED and solar cells • Propel® 300 for GaN on Si MicroLED for AR / VR and optical communications ~$300M ~$550M GaN Power • Propel® single wafer MOCVD platform for 200mm and 300mm GaN • Propel® 300mm GaN on Si evaluation system at leading IDM customer • Received Propel® 300mm pilot line order in 2H ‘25 ~$150M ~$250M Veeco’s Technology Supports AI, Power Efficiency, and Advanced Connectivity, which are Reshaping the Industry 2026 2030 Total Served Available Market GaN Power Silicon Photonics Other Photonics RF & Other Services Projected ~15% CAGR ~$1.0B ~$2.0B |
| 7 Veeco’s Critical Role in Compound Semi: Indium Phosphide Laser Solutions Repeat cycle depending on device Epitaxy Patterning Metallization Anneal / Cleave Etch Laser Facet Coating Lumina® MOCVD InP Platform Size of bubble represents approximate market opportunity Veeco Provides Differentiated Solutions for Key Steps in manufacturing InP Lasers Driven by AI Infrastructure Cumulative at least $2B Total Market Opportunity over the next several years WaferEtch® / WaferStorm® Wet Processing Spector® Ion Beam Deposition Source: Veeco Total Market Opportunity based on TrendFocus, Gartner, Yole Group and internal analysis |
| John Kiernan CFO Overview 8 |
| 9 Revenue by Market Scientific & Other Semiconductor Compound Semiconductor Data Storage 10% 11% 11% 68% United States $193M Revenue Trend ($M) Q2 25 Q1 26 Q2 26 Semiconductor 124 109 131 Compound Semi 14 19 21 Data Storage 12 10 22 Scientific & Other 16 20 20 Total 166 158 193 Revenue Trend ($M) Q2 25 Q1 26 Q2 26 APAC 98 90 70 USA 22 32 59 China 27 20 48 EMEA & ROW 18 16 16 Total 166 158 193 Q2 2026 Revenue by Market & Region Amounts may not calculate precisely due to rounding. Revenue by Region ROW is negligible 31% 25% 8% 36% United States EMEA & ROW APAC China |
| 10 Amounts may not calculate precisely due to rounding. A reconciliation of GAAP to Non-GAAP financial measures can be found in the backup section of this presentation. In millions (except per share amounts) GAAP Non-GAAP Non-GAAP Q1 26 Q2 26 Q1 26 Q2 26 Q2 26 Guidance (as of May 5th, 2026) Revenue $158.3 $193.5 $158.3 $193.5 $170M - $190M Gross Profit 55.8 74.8 57.3 76.4 Gross Margin 35.3% 38.7% 36.2% 39.5% 38% - 40% Operating Expenses 58.5 63.0 48.8 53.3 $52M - $55M Operating Income (Loss) (2.7) 11.9 8.6 23.1 Net Income (Loss) (0.3) 11.9 8.9 21.8 $12M - $21M Diluted Earnings Per Share (Loss) (0.01) 0.18 0.14 0.33 $0.20 - $0.32 Diluted Shares 60.4 66.8 61.9 66.8 Q2 2026 Operating Results |
| 11 Amounts may not calculate precisely due to rounding. A reconciliation of GAAP to Non-GAAP financial measures can be found in the backup section of this presentation. Balance Sheet and Cash Flow Highlights $ millions Q1 2026 Q2 2026 Cash & Short-Term Investments 383 429 Accounts Receivable 151 148 Inventories 282 292 Accounts Payable 60 57 Long-Term Debt 226 227 Cash Flow from Operations 8 51 Capital Expenditures 5 4 DSO (days) 86 69 DIO (days) 245 218 DPO (days) 54 44 |
| 12 Q3 & FY 2026 Outlook A reconciliation of GAAP to Non-GAAP financial measures can be found in the backup section of this presentation. Q3 2026 FY 2026 GAAP Non-GAAP GAAP Non-GAAP Revenue $200M - $220M $200M - $220M $780M - $810M $780M - $810M Gross Margin 40% - 42% 41% - 42% 39% - 41% 40% - 42% Operating Expenses $66M - $67M $57M - $58M $253M - $263M $215M - $225M Net Income $14M – $23M $23M - $33M $52M - $68M $91M - $107M Diluted Earnings Per Share $0.20 – $0.34 $0.35 - $0.49 $0.78 - $1.02 $1.36 - $1.61 |
| Q&A 13 |
| Backup & Financial Tables 14 |
| 15 $M 2022 2023 2024 2025 2026 FY Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Q2 Semi 369.4 93.1 106.3 98.2 115.2 412.7 120.4 109.9 124.1 112.1 466.6 123.8 123.9 118.3 110.5 476.6 109.0 130.7 Compound Semi 121.2 21.2 24.1 25.7 16.3 87.3 21.0 18.2 15.6 22.8 77.6 14.4 14.2 10.9 20.1 59.6 18.8 20.5 Data Storage 87.5 21.5 13.9 34.0 19.1 88.5 18.0 34.0 32.8 14.1 98.9 6.7 12.4 10.0 10.2 39.2 10.2 22.2 Scientific & Other 68.0 17.7 17.4 19.6 23.4 78.0 15.1 13.8 12.4 33.0 74.2 22.4 15.7 26.7 24.2 88.9 20.3 20.1 Total 646.1 153.5 161.6 177.4 173.9 666.4 174.5 175.9 184.8 182.1 717.3 167.3 166.1 165.9 165.0 664.3 158.3 193.5 Historical Revenue by End-Market Amounts may not calculate precisely due to rounding. |
| 16 2029 Convertible Notes Outstanding Convertible Notes Due June 2029 Principal Amount Carrying Value Coupon Annual Cash Interest Annual Non-Cash Interest Initial Conversion Price $230M $227M 2.875% $6.6M $1.1M $29.22 As of June 30, 2026 * The Company is required to settle the principal amount of the 2029 Convertible Notes in cash,and has the option to settle the excess above principal in any combination of cash or shares. As such, only “in-the-money” shares above the implied conversion price of $29.22 are added to the diluted share count, and there is no interest expense add-back to the numerator for purposes of calculating diluted EPS. Effect of Convertible Notes on Diluted EPS (GAAP and Non-GAAP)* Average Stock Price per Common Share Incremental Dilutive Shares (in thousands) $29.00 - $30.00 205 $35.00 1,300 $40.00 2,121 $45.00 2,760 $50.00 3,271 $55.00 3,689 $60.00 4,037 $65.00 4,332 $70.00 4,585 $75.00 4,804 $80.00 4,996 |
| 17 Note on Reconciliation Tables These tables include financial measures adjusted for the impact of certain items; these financial measures are therefore not calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). These Non-GAAP financial measures exclude items such as: share-based compensation expense; charges relating to restructuring initiatives; non-cash asset impairments; certain other non-operating gains and losses; and acquisition-related items such as transaction costs, non-cash amortization of acquired intangible assets, incremental transaction-related compensation, and certain integration costs. These Non-GAAP financial measures may be different from Non-GAAP financial measures used by other companies. Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. By excluding these items, Non-GAAP financial measures are intended to facilitate meaningful comparisons to historical operating results, competitors' operating results, and estimates made by securities analysts. Management is evaluated on key performance metrics including Non-GAAP Operating Income, which is used to determine management incentive compensation as well as to forecast future periods. These Non-GAAP financial measures may be useful to investors in allowing for greater transparency of supplemental information used by management in its financial and operational decision-making. In addition, similar Non-GAAP financial measures have historically been reported to investors; the inclusion of comparable numbers provides consistency in financial reporting. Investors are encouraged to review the reconciliation of the Non-GAAP financial measures used in this news release to their most directly comparable GAAP financial measures. |
| Supplemental Information—GAAP to Non-GAAP Reconciliation $ millions Q1 26 Q2 26 Net sales $158.3 $193.5 GAAP gross profit 55.8 74.8 GAAP gross margin 35.3% 38.7% Add: Share-based comp 1.5 1.6 Non-GAAP gross profit $57.3 $76.4 Non-GAAP gross margin 36.2% 39.5% $ millions Q1 26 Q2 26 GAAP Net income (loss) ($0.3) $11.9 Add: Share-based comp 8.5 9.2 Add: Amortization 0.7 0.6 Add: Merger related expenses 2.0 1.5 Add: Interest expense (income) (1.2) (1.2) Add: Tax expense (benefit) (1.2) 1.2 Non-GAAP operating income $8.6 $23.1 $ millions, except per share amounts Q1 26 Q2 26 GAAP Basic weighted average shares 60.4 61.1 GAAP Diluted weighted average shares 60.4 66.8 GAAP Basic EPS ($0.01) $0.19 GAAP Diluted EPS ($0.01) $0.18 GAAP Net income (loss) ($0.3) $11.9 Add: Share-based comp 8.5 9.2 Add: Amortization 0.7 0.6 Add: Merger related expenses 2.0 1.5 Add: Non-cash interest expense 0.2 0.3 Add: Tax adjustment from GAAP to Non-GAAP (2.3) (1.7) Non-GAAP net income 8.9 21.8 Non-GAAP basic EPS $0.15 $0.36 Non-GAAP diluted EPS $0.14 $0.33 Non-GAAP basic weighted average shares 60.4 61.1 Non-GAAP diluted weighted average shares 61.9 66.8 $ millions Q1 26 Q2 26 GAAP operating expenses $58.5 $63.0 Share-based compensation (7.0) (7.6) Amortization (0.7) (0.6) Merger related expenses (2.0) (1.5) Non-GAAP operating expenses $48.8 $53.3 Amounts may not calculate precisely due to rounding. 18 |
| $ millions Non-GAAP Adjustments GAAP Share-Based Compensation Amortization Other Non-GAAP Net Sales $193.5 $193.5 Gross Profit 74.8 1.6 — — 76.4 Gross Margin 38.7% 39.5% Operating Expenses $63.0 (7.6) (0.6) (1.5) $53.3 Operating Income $11.9 9.2 0.6 1.5 $23.1 Net Income $11.9 9.2 0.6 0.1 $21.8 Q2 2026 Actual: GAAP to Non-GAAP Reconciliation Income per Diluted Common Share GAAP Non-GAAP Net Income available to common shareholders $11.9 $21.8 Basic weighted average common shares 61.1 61.1 Add: Dilutive effect of share-based awards 2.0 2.0 Add: Dilutive effect of 2029 Convertible Senior Notes 3.7 3.7 Diluted weighted average common shares 66.8 66.8 Basic income per common share $0.19 $0.36 Diluted income per common share $0.18 $0.33 Other Non-GAAP Adjustments Merger related expenses 1.5 Subtotal 1.5 Non-cash Interest Expense 0.3 Non-GAAP tax adjustment (1.7) Total Other $0.1 Amounts may not calculate precisely due to rounding. |
| Reconciliation of GAAP to non-GAAP Financial Data Non-GAAP Adjustments GAAP Share-Based Compensation Amortization Other Non-GAAP Net Sales $200–$220 $200–$220 Gross Profit 80–92 1 — — 82–93 Gross Margin 40%–42% 41%–42% Operating Expenses $66–$67 (8) — (1) $57–$58 Operating Income $14–$25 9 — 1 $25–$35 Net Income $14–$23 9 — — $23–$33 Income per Diluted Share $0.20–$0.34 $0.35–$0.49 Q3 2026 Guidance ($ millions, except per share amounts) Reconciliation of GAAP Net Income to non-GAAP Operating Income GAAP Net Income $14–$23 Share-Based Compensation 9 Merger related expenses 1 Interest expense (income) (1) Income tax expense (benefit) 2-3 Non-GAAP Operating Income $25–$35 Amounts may not calculate precisely due to rounding. Income per Diluted Common Share GAAP Non-GAAP Net income available to common shareholders $14–$23 $23–$33 Basic weighted average common shares 61 61 Add: Dilutive effect of share-based awards 2 2 Add: Dilutive effect of 2029 Convertible Senior Notes 4 4 Diluted weighted average common shares 67 67 Income per diluted common share $0.20-$0.34 $0.35-$0.49 |
| Reconciliation of GAAP to non-GAAP Financial Data Non-GAAP Adjustments GAAP Share-Based Compensation Amortization Other Non-GAAP Net Sales $780–$810 $780–$810 Gross Profit 306–334 6 — — 312–340 Gross Margin 39%–41% 40%–42% Operating Expenses $253–$263 (30) (2) (6) $215–$225 Operating Income $53–$71 36 2 6 $97–$115 Net Income $52–$68 36 2 1 $91–$107 Income per Diluted Share $0.78–$1.02 $1.36–$1.61 FY 2026 Guidance ($ millions, except per share amounts) Reconciliation of GAAP Net Income to non-GAAP Operating Income GAAP Net Income $52–$68 Share-Based Compensation 36 Amortization 2 Merger related expenses 6 Interest expense (income) (4) Income tax expense (benefit) 5-7 Non-GAAP Operating Income $97–$115 Amounts may not calculate precisely due to rounding. Income per Diluted Common Share GAAP Non-GAAP Net income available to common shareholders $52–$68 $91–$107 Basic weighted average common shares 62 62 Add: Dilutive effect of share-based awards 1 1 Add: Dilutive effect of 2029 Convertible Senior Notes 4 4 Diluted weighted average common shares 67 67 Income per diluted common share $0.78-$1.02 $1.36-$1.61 |
